WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) View the PDF document
Table of Contents
View the documentWHO Drug Information
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsQuality Assurance Issues
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Open this folder and view contentsRegulatory and Safety Matters*
Close this folderATC/DDD Classification
View the documentFinal list
View the documentTemporary list
Open this folder and view contentsRegulatory Information
View the documentRecommended International Nonproprietary Names (rec. Inn): List 46
View the documentSelected WHO Publications of Related Interest
 

Final list

The following final anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place on 21 October 2001. They are included in the January 2002 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology, e-mail: whocc@nmd.no.

New ATC level codes (other than 5th level):

 
 

Agents used in photodynamic therapy

L01XD

 

Bone morphogenetic proteins

M05BC

     

New ATC 5th level codes:

 
 

acetyldigoxin combination

C01AA52

 

agalsidase alfa

A16AB03

 

agalsidase beta

A16AB04

 

amlexanox

A01AD07

 

anakinra

L04AA14

 

arsenic trioxide

L01XX27

 

ascorbic acid

G01AD03

 

ascorbic acid

S01XA15

 

bisoxatin

A06AB09

 

BMP-2

M05BC01

 

BMP-7

M05BC02

 

cilnidipine

C08CA14

 

crilanomer

D03AX09

 

darbepoetin alfa

B03XA02

 

denileukin diftitox

L01XX29

 

dienogest and estrogen

G03FA15

 

diflucortolone

D07XC04

 

dimethyl sulfoxide

G04BX13

 

drotrecogin alfa (activated)

B01AD10

 

esomeprazole, amoxicillin and clarithromycin

A02BD06

 

fomepizole

V03AB34

 

formoterol and other drugs for obstructive airway diseases

R03AK07

 

fulvestrant

L02BA03

 

gadobutrol

V08CA09

 

hemoglobin raffimer

B05AA09

 

imatinib

L01XX28

 

insulin glargine

A10AE04

     

New ATC 5th level codes:

 
 

levocetirizine

R06AE08

 

lutropin alfa

G03GA07

 

methyl aminolevulinate

L01XD03

 

monobenzone

D11AX13

 

multienzymes and acid preparations

A09AC02

 

omalizumab

R03DX05

 

phloroglucinol

A03AX12

 

rupatadine

R06AX28

 

sodium selenite

A12CE02

 

sodium tartrate

A06AD21

 

tacrolimus

D11AX14

 

talinolol

C07AB13

 

tegafur, combinations

L01BC53

 

thioacetazone, combinations

J04AM04

 

tiotropium bromide

R03BB04

 

trimegestone and estrogen

G03FB11

 

unoprostone

S01EX04

 

vaginal ring with progestogen and estrogen

G02BB01

 

zinc acetate, basic

A16AX05

     

ATC code changes

 

Previous:

porfimer sodium

L01XX15

New:

porfimer sodium

L01XD01

Previous:

verteporfin

L01XX26

New:

verteporfin

L01XD02

Previous:

alginic acid

A02EA01

New:

alginic acid

A02BX13

Previous:

silicones

A02DA01

New:

silicones

A03AX13

ATC name changes

 

Previous: Antacids, drugs for treatment of peptic ulcer and flatulence

 

New: Drugs for acid related disorders

A02

Previous: Drugs for treatment of peptic ulcer

 

New: Drugs for peptic ulcer and gastroesophageal reflux disease (GORD)

A02B

Previous: Other drugs for treatment of peptic ulcer

 

New: Other drugs for peptic ulcer and gastroesophageal reflux disease (GORD)

A02BX

Previous: Other antacids, drugs for treatment of peptic ulcer and flatulence

 

New: Other drugs for acid related disorders

A02X

Previous: Antispasmodic and anticholinergic agents and propulsives

 

New: Drugs for functional gastrointestinal disorders

A03

Previous: Synthetic antispasmodic and anticholinergic agents

 

New: Drugs for functional bowel disorders

A03A

Previous: Other synthetic anticholinergic agents

 

New: Other drugs for functional bowel disorders

A03AX

Previous: Drugs affecting mineralization

 

New: Drugs affecting bone structure and mineralization

M05B

Previous: Anti-asthmatics

 

New: Drugs for obstructive airway diseases

R03

Previous: Adrenergics and other anti-asthmatics

 

New: Adrenergics and other drugs for obstructive airway diseases

R03AK

Previous: Epinephrine and other anti-asthmatics

 

New: Epinephrine and other drugs for obstructive airway diseases

R03AK01

Previous: Isoprenline and other anti-asthmatics

 

New: Isoprenaline and other drugs for obstructive airway diseases

R01AK02

Previous: Fenoterol and other anti-asthmatics

 

New: Fenoterol and other drugs for obstructive airway diseases

R01AK03

Previous: Salbutamol and other anti-asthmatics

 

New: Salbutamol and other drugs for obstructive airway diseases

R03AK04

Previous: Reproterol and other anti-asthmatics

 

New: Reproterol and other drugs for obstructive airway diseases

R03AK05

Previous: Salmeterol and other anti-asthmatics

 

New: Salmeterol and other drugs for obstructive airway diseases

R03AK06

Previous: Other anti-asthmatics, inhalants

 

New: Other drugs for obstructive airway diseases, inhalants

R03B

Previous: Other anti-asthmatics, inhalants

 

New: Other drugs for obstructive airway diseases, inhalants

R03BX

Previous: Adrenergics and other anti-asthmatics

 

New: Adrenergics and other drugs for obstructive airway diseases

R03CK

Previous: Other anti-asthmatics for systemic use

 

New: Other systemic drugs for obstructive airway diseases

R03D

Previous: Other anti-asthmatics for systemic use

 

New: Other systemic drugs for obstructive airway diseases

R03DX

New DDDs:

INN/common name

DDD

Unit

Route of
Administration

ATC code

almotriptan

12.5

mg

O

N02CC05

buprenorphine

8

mg

O

N07BC01

cilnidipine

10

mg

O

C08CA14

darbepoetin alfa

4.5

mcg

P

B03XA02

desloratadine

5

mg

O

R06AX27

itraconazole

0.2

g

P

J02AC02

levocetirizine

5

mg

O

R06AE08

mifepristone

0.6

g

O

G03XB01

mycofenolic acid

2

g

P

L04AA06

nimesulide

0.2

g

O

M01AX17

peginterferon alfa-2b

7.5

mcg

P

L03AB10

propacetamol

6

g

P

N02BE05

talinolol

0.1

g

O

C07AB13

tobramycin

0.3

g

Inhal. sol.

J01GB01

zinc acetate, basic

0.15

g

O

A16AX05

         

DDD changes:

       

Previous: erythropoietin

2

TU

P

 

New: erythropoietin

1

TU

P

B03XA01

Previous: risedronic acid

30

mg

O

 

New: risedronic acid

5

mg

O

M05BA07

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018